Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection ofEscherichia coli and Klebsiella pneumoniaeharbouring serine- and New Delhi metallo-β-lactamases
Authors:
- 12 August 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 76 (11) , 2875-2883
Abstract
Ceftazidime/avibactam is not active against MBL-producing bacteria. Combining ceftazidime/avibactam or avibactam with aztreonam can counter the resistance of MBL-producing Enterobacterales. The aim of this study was to evaluate whether the addition of avibactam could reduce or close the mutant selection window (MSW) of aztreonam in Escherichia coli and Klebsiella pneumoniae harbouring MBLs; MSW is a pharmacodynamic (PD) parameter for the selection of emergent resistant mutants. In vitro susceptibility of 19 clinical isolates to ceftazidime/avibactam, aztreonam alone, and in co-administration (aztreonam/ceftazidime/avibactam and aztreonam/avibactam) was determined, as well as the mutant prevention concentration (MPC). The fraction of time within 24 h that the free drug concentration was within the MSW (fTMSW) and the fraction of time that the free drug concentration was above the MPC (fT>MPC) in both plasma and epithelial lining fluid (ELF) were determined from simulations of 10 000 profiles. The joint PTA was used to derive a joint cumulative fraction of response (CFR). All isolates were resistant to ceftazidime/avibactam or aztreonam. Combining aztreonam and avibactam or ceftazidime/avibactam resulted in synergistic bactericidal activities against all isolates. Synergism was primarily due to the aztreonam/avibactam combination. For aztreonam/avibactam dosing regimens evaluated in clinical trials, fT>MPC values were >90% and >80%, whereas fTMSW measures were fT>MPC and reducing fTMSW.Keywords
Funding Information
- Shandong Provincial Natural Science Foundation (ZR2019BC025)
- Science and Technology Plan of Yantai City (2019MSGY132)
- Science and Technology Development Plan of Yeda Hospital of Yantai (201801)
- Foundation of the Affiliated Hospital of Qingdao University
- Youth Foundation of the Affiliated Hospital of Qingdao University
This publication has 39 references indexed in Scilit:
- Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2016
- In vitropharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organismsJournal of Antimicrobial Chemotherapy, 2016
- Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung InfectionAntimicrobial Agents and Chemotherapy, 2016
- Urinary Tract Infections in Older WomenJAMA, 2014
- Does broad-spectrum -lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria?Journal of Antimicrobial Chemotherapy, 2011
- Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological studyThe Lancet Infectious Diseases, 2010
- Pharmacokinetic/Pharmacodynamic Analysis of the Influence of Inoculum Size on the Selection of Resistance in Escherichia coli by a Quinolone in a Mouse Thigh Bacterial Infection ModelAntimicrobial Agents and Chemotherapy, 2009
- A unified anti-mutant dosing strategyJournal of Antimicrobial Chemotherapy, 2008
- Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infectionJournal of Antimicrobial Chemotherapy, 2007
- Comparison of β-lactams in counter-selecting resistance of Pseudomonas aeruginosaDiagnostic Microbiology and Infectious Disease, 2005